4-(hydroxymethyl)-1-(piperidin-2-yl)piperidine | 199117-79-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-(hydroxymethyl)-1-(piperidin-2-yl)piperidine
• 英文别名: (1-(pyridin-2-yl)piperidin-4-yl)methanol；N-(pyridin-2-yl)-4-piperidinemethanol；N-(2-pyridyl)-4-piperidinemethanol；(1-pyridin-2-ylpiperidin-4-yl)methanol
• CAS: 199117-79-8
• 化学式: C₁₁H₁₆N₂O
• mdl: MFCD11044207
• 分子量: 192.261
• InChiKey: GVAWIUOVSIOZFQ-UHFFFAOYSA-N

物化性质

• 沸点：
  351.5±12.0 °C(Predicted)
• 密度：
  1.108±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.545
• 拓扑面积：
  36.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(hydroxymethyl)-1-(piperidin-2-yl)piperidine 在 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 4-<<-(pyridin-2-yl)piperidin-4-yl>methoxy>benzaldehyde
  参考文献：
  名称：

  Novel Euglycemic and Hypolipidemic Agents. 4. Pyridyl- and Quinolinyl-Containing Thiazolidinediones

  摘要：

  A series of substituted pyridyl- and quinolinyl-containing 2,4-thiazolidinediones having interesting cyclic amine as a linker have been synthesized. Both unsaturated thiazolidinediones 5 and saturated thiazolidinediones 6 and their various salts were evaluated in db/db mice for euglycemic and hypolipidemic effects and compared with BRL compound 11 and BRL-49653, respectively. Some of the potent compounds were converted to various salts in order to obtain improved activities. Among all the salts evaluated, the maleate salt of unsaturated TZD 5a was found to be a very potent euglycemic and hypolipidemic compound. Some of the more interesting compounds have also been evaluated in ob/ob mice and compared with rosiglitazone (maleate salt of BRL-49653). Oral glucose tolerance tests were performed in both db/db and ob/ob mice. Pharmacokinetic studies of 5a maleate are also reported. Receptor binding studies of PPAR gamma by 5a/5a maleate did not show any significant transactivation of PPAR alpha or PPAR gamma.

  DOI：

  10.1021/jm980622j
• 作为产物：
  描述：

  4-哌啶甲醇 、 2-氟吡啶 在 N,N-二异丙基乙胺 作用下， 反应 3.0h， 以37.97%的产率得到4-(hydroxymethyl)-1-(piperidin-2-yl)piperidine
  参考文献：
  名称：

  DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF

  摘要：

  本发明涉及一组1-[(E)-3-(3,4,5-三甲氧基苯基)丙-2-烯酰基]-2,3-二氢吡啶-6-酮（长椒碱）衍生物、类似物及其药学上可接受的盐。本发明还涉及含有长椒碱衍生物的药物组合物和配方；以及利用这些衍生物和类似物治疗癌症、减少炎症和/或治疗自身免疫或炎症性疾病。

  公开号：

  US20200377510A1

文献信息

• [EN] DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF<br/>[FR] DÉRIVÉS DE PIPERLONGUMINE ET LEURS UTILISATIONS
  申请人：AURANSA INC

  公开号：WO2019103897A1

  公开（公告）日：2019-05-31

  The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3- dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to processes for preparing the same; a pharmaceutical composition and formulation containing a derivative of piperlogumine; and use of the derivatives and analogs for treating cancer.

  本发明涉及一组1-[(E)-3-(3,4,5-三甲氧基苯基)丙-2-烯酰基]-2,3-二氢吡啶-6-酮（长椒碱）衍生物、类似物及其药学上可接受的盐。本发明还涉及制备这些衍生物的方法；含有长椒碱衍生物的药物组合物和配方；以及利用这些衍生物和类似物治疗癌症。
• Direct Uncatalyzed Amination of 2-Chloropyridine Using a Flow Reactor
  作者：Bruce Hamper、Eden Tesfu

  DOI：10.1055/s-2007-985574

  日期：——

  Chloropyridines are efficiently converted into 2-amino­pyridines by uncatalyzed nucleophilic aromatic substitution (SNAr) in NMP using a continuous-flow reactor. A variety of secondary amines undergo SNAr with both electron-rich and electron-deficient 2-chloropyridines to afford 2-aminopyridines in good to excellent yield. The flow reactor, which provides a short reaction time and high temperatures up to 300 °C, can overcome the activation barrier for reactions with unactivated substrates. Short reaction times result in fewer side products and can afford milligram to multigram ­quantities of product using continuous flow.

  氯代吡啶在无催化剂的亲核芳香取代（SNAr）作用下，通过连续流动反应器在NMP中高效转化为2-氨基吡啶。多种仲胺能够与电子丰富和电子缺乏的2-氯代吡啶进行SNAr反应，以良好至优异的产率得到2-氨基吡啶。这种连续流动反应器提供了短暂的反应时间和高达300°C的高温，能够克服非活化底物反应的活化能障碍。短暂的反应时间导致副产品较少，并且使用连续流动的方式可以在毫克至多克的量级上得到产物。
• Heterocyclic compounds having antidiabetic, hypolipidaemic,
  申请人：Dr. Reddy's Research Foundation

  公开号：US05801173A1

  公开（公告）日：1998-09-01

  Novel antidiabetic compounds, their tautomeric forms, their derivatives, their steroisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceuticaly acceptable compositions containing them; methods for preparing the antidiabetic compounds and their uses.

  新型抗糖尿病化合物，它们的互变异构体，它们的衍生物，它们的立体异构体，它们的多晶形态，它们的药学上可接受的盐，它们的药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物；制备抗糖尿病化合物的方法及其用途。
• [EN] THIAZOLIDINEDIONE COMPOUNDS HAVING ANTIDIABETIC, HYPOLIPIDAEMIC, ANTIHYPERTENSIVE PROPERTIES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF<br/>[FR] COMPOSES DE THIAZOLIDINEDIONE PRESENTANT DES PROPRIETES ANTIDIABETIQUES, HYPOLIPIDEMIANTES, ANTIHYPERTENSIVES, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：DR. REDDY'S RESEARCH FOUNDATION

  公开号：WO1997041120A1

  公开（公告）日：1997-11-06

  (EN) Novel thiazolidinedione antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceuticals acceptable compositions containing them; methods for preparing the antidiabetic compounds and their uses.(FR) L'invention concerne de nouveaux composés antidiabétiques de thiazolidinedione, leurs formes tautomères, leurs dérivés, leurs stéréoisomères, leurs polymorphes, leurs sels pharmaceutiquement acceptables, leurs solvates pharmaceutiquement acceptables et des compositions pharmaceutiquement acceptables les contenant, des procédés de préparation des composés antidiabétiques et leurs utilisations.

  (中) 一种新的噻唑烷酮类抗糖尿病化合物、它们的互变异构体、衍生物、立体异构体、多晶形态、药用可接受的盐、药用可接受的溶剂和含有它们的药用可接受的组合物；制备抗糖尿病化合物的方法及其用途。
• THIAZOLIDINEDIONE COMPOUNDS HAVING ANTIDIABETIC, HYPOLIPIDAEMIC, ANTIHYPERTENSIVE PROPERTIES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
  申请人：DR. REDDY'S RESEARCH FOUNDATION

  公开号：EP0923580A1

  公开（公告）日：1999-06-23